Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonistsMIN AMY XIANG; CHEN, Robert H; DEMAREST, Keith T et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 12, pp 3143-3146, issn 0960-894X, 4 p.Article

Vascular Effects of RWJ-676070, a Selective Combined V_1a/V₂ Vasopressin Receptor AntagonistCOLTAMAI, L; BUCHER, M; MAILLARD, M. P et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 2, pp 145-148, issn 0009-9236, 4 p.Article

The multifunctional protein GClq-R interacts specifically with the i3 loop arginine cluster of the vasopressin V₂ receptorGRANIER, Sébastien; JEAN-ALPHONSE, Frédéric; BELLOT, Gaétan et al.Regulatory peptides. 2008, Vol 148, Num 1-3, pp 76-87, issn 0167-0115, 12 p.Article

TolvaptanDUBOIS, Eline A; RISSMANN, Robert; COHEN, Adam F et al.British journal of clinical pharmacology. 2012, Vol 73, Num 1, pp 9-11, issn 0306-5251, 3 p.Article

Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentrationYING TIAN; SERINO, Ryota; VERBALIS, Joseph G et al.American journal of physiology. Renal physiology. 2004, Vol 56, Num 4, pp F797-F805, issn 1931-857XArticle

GIP, a G-protein-coupled receptor interacting proteinINNAMORATI, Giulio; INSUK WHANG, Michael; MOLTENI, Raffaella et al.Regulatory peptides. 2002, Vol 109, Num 1-3, pp 173-179, issn 0167-0115, 7 p.Conference Paper

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label StudyFUKUNAMI, Masatake; MATSUZAKI, Masunori; HORI, Masatsugu et al.Cardiovascular drugs and therapy. 2011, Vol 25, issn 0920-3206, S47-S56, SUP1Article

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trialGHEORGHIADE, Mihai; GATTIS, Wendy A; OUYANG, John et al.JAMA, the journal of the American Medical Association. 2004, Vol 291, Num 16, pp 1963-1971, issn 0098-7484, 9 p.Article

Through the central V2, not V1 receptors influencing the endogenous opiate peptide system, arginine vasopressin, not oxytocin in the hypothalamic paraventricular nucleus involves in the antinociception in the ratJUN YANG; CHEN, Jian-Min; SONG, Cao-You et al.Brain research. 2006, Vol 1069, pp 127-138, issn 0006-8993, 12 p.Article

Phase III Clinical Pharmacology Study of TolvaptanINOMATA, Takayuki; IZUMI, Tohru; MATSUZAKI, Masunori et al.Cardiovascular drugs and therapy. 2011, Vol 25, issn 0920-3206, S57-S65, SUP1Article

Downregulation of the V2 vasopressin receptor in dehydration : mechanisms and role of renal prostaglandin synthesisMACHIDA, Kenji; WAKAMATSU, Shiho; NONOGUCHI, Hiroshi et al.American journal of physiology. Renal physiology. 2007, Vol 61, Num 4, issn 1931-857X, F1274-F1282Article

Effects of a selective vasopressin V₂ receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosisWONG, Florence; GINES, Pere; WATSON, Hugh et al.Journal of hepatology. 2010, Vol 53, Num 2, pp 283-290, issn 0168-8278, 8 p.Article

Experience of a Vasopressin Receptor Antagonist, Tolvaptan, Under the Unique Indication in Japanese Heart Failure PatientsKINUGAWA, K; IMAMURA, T; KOMURO, I et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 4, pp 449-451, issn 0009-9236, 3 p.Article

Potential of Nonpeptide (Ant)agonists to Rescue Vasopressin V2 Receptor Mutants for the Treatment of X-linked Nephrogenic Diabetes InsipidusLOS, E. L; DEEN, P. M. T; ROBBEN, J. H et al.Journal of neuroendocrinology. 2010, Vol 22, Num 5, pp 393-399, issn 0953-8194, 7 p.Article

Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severityWONG, Florence; WATSON, Hugh; GERBES, Alexander et al.Gut. 2012, Vol 61, Num 1, pp 108-116, issn 0017-5749, 9 p.Article

ETUDE DES MECANISMES MOLECULAIRES RESPONSABLES DE L'EXPRESSION DU GENE CODANT POUR LE RECEPTEUR DE TYPE 2 DE L'ARGININE VASOPRESSINE = STUDY OF THE MOLECULAR MECHANISMS RESPONSIBLE FOR THE TISSUE-SPECIFIC EXPRESSION OF ARGININE VASOPRESSIN TYPE 2 RECEPTORCalmont, Amelie; Ronco, Pierre.2001, 233 p.Thesis

High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH)KENZ, S; HAAS, C. S; WERTH, S. C et al.Annals of oncology. 2011, Vol 22, Num 12, issn 0923-7534, p. 2696Article

Nonclinical Pharmacokinetics of a New Nonpeptide V2 Receptor Antagonist, TolvaptanFURUKAWA, Masayuki; UMEHARA, Ken; KASHIYAMA, Eiji et al.Cardiovascular drugs and therapy. 2011, Vol 25, issn 0920-3206, S83-S89, SUP1Article

Nonclinical Safety Profile of TolvaptanOI, Akihide; MORISHITA, Katsumi; UESUGI, Tohru et al.Cardiovascular drugs and therapy. 2011, Vol 25, issn 0920-3206, S91-S99, SUP1Article

Downregulation of vasopressin V₂ receptor promoter activity via V_1a receptor pathwayIZUMI, Yuichiro; NAKAYAMA, Yushi; MORI, Tomohiko et al.American journal of physiology. Renal physiology. 2007, Vol 61, Num 5, issn 1931-857X, F1418-F1426Article

Attenuation of renal vasopressin V₂ receptor upregulation by bosentan, an ETA/ETB receptor antagonistWONG, Norman L. M; SONNTAG, Marc; TSUI, Joseph K. C et al.Metabolism, clinical and experimental. 2003, Vol 52, Num 9, pp 1141-1146, issn 0026-0495, 6 p.Article

Clausal architecture in Early Old FrenchLABELLE, Marie.Lingua (Haarlem. Print). 2007, Vol 117, Num 1, pp 289-316, issn 0024-3841, 28 p.Article

Tolvaptan, a selective oral vasopressin V₂-receptor antagonist, for hyponatremiaSCHRIER, Robert W; GROSS, Peter; GHEORGHIADE, Mihai et al.The New England journal of medicine. 2006, Vol 355, Num 20, pp 2099-2112, issn 0028-4793, 14 p.Article

Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humansBANKIR, Lise; FERNANDES, Sandrine; BARDOUX, Pascale et al.Journal of the American Society of Nephrology. 2005, Vol 16, Num 7, pp 1920-1928, issn 1046-6673, 9 p.Article

Tolvaptan for Heart Failure Patients with Volume OverloadHORI, Masatsugu.Cardiovascular drugs and therapy. 2011, Vol 25, issn 0920-3206, S1-S4, SUP1Article